A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

NCT03019536 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: LY3303560 - IV
DRUG: Placebo - IV
DRUG: Florbetapir F 18
DRUG: Flortaucipir F18

Sponsor

Eli Lilly and Company